近日,阿斯利康与珐博进有限公司(简称“珐博进”)达成协议,将以约1.6亿美元(约合人民币12亿元)收购珐博进中国,拿下罗沙司他在中国的所有权利。有业内人士向《经济参考报》记者表示,作为全球医药巨头的阿斯利康并购中国公司,显示其代表行业及跨国公司持续看好中国发展机遇,也向市场传递了一个明确信号,即中国本土的生物科技和制药企业仍具备巨大的成长与投资潜力。 据介绍,罗沙司他目前用于慢性肾脏病(CKD)...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.